39
Participants
Start Date
October 21, 2021
Primary Completion Date
September 21, 2023
Study Completion Date
October 31, 2027
OST31-164
Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
Montefiore Medical Center, The Bronx
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Nemours/ Alfred I duPont Hospital for Children, Wilmington
Johns Hopkins Medical Center, Baltimore
Children's Healthcare of Atlanta, Atlanta
Johns Hopkins All Children's Hospital, St. Petersburg
St. Jude Children's Research Hospital, Memphis
Nationwide Children's Hospital, Columbus
University of Minnesota/Masonic Cancer Center, Minneapolis
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
UT Southwestern Medical Center, Dallas
Children's Hospital of Colorado, Aurora
Kaiser Permanente Downey Medical Center, Los Angeles
Children's Hospital of Orange County, Orange
Rady Children's Hospital, San Diego
Oregon Health & Science University, Portland
Seattle Children's Hospital, Seattle
Connecticut Children's, Hartford
Dana-Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Lead Sponsor
Emerald Clinical Inc.
INDUSTRY